Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
1. Those who voluntarily participated in this trial and provided informed consent;
2. Gender unlimited，18<Age≤75;
3. Estimated life expectancy of minimum of 12 weeks;
4. ECOG 0-2;
1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
3. Pregnant (or lactating) women;
4. Patients with HIV infection;